Harry P. Erba

Also affiliated with Cancer Institute (WIA), Duke Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from NF1 Inactivation in Adult Acute Myelogenous Leukemia

(2023)10.1158/1078-0432.c.6519537.v1

Top 100%

0DataRank

Top 100%0 citations

Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston +14 more

Papers

Driven by 34 papers — median percentile 0. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

New England Journal of Medicine(2024)10.1056/nejmoa2312948

N/A

4.4DataRank · unranked

227 citations

Zhuoxin Sun, Ryan J. Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang +37 more

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood(2020)10.1182/blood.2020007732

N/A

4.0DataRank · unranked

322 citations

Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani +43 more

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Blood Advances(2022)10.1182/bloodadvances.2022008216

N/A

1.8DataRank · unranked

72 citations

Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt +12 more

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Haematologica(2023)10.3324/haematol.2023.283520

N/A

1.1DataRank · unranked

35 citations

Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith +8 more

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7500

N/A

0.687DataRank · unranked

14 citations

Jun Yin, Jennifer R. Brown, Shira Dinner, Gerard Lozanski, Richard F. Little +15 more

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7006

N/A

0.584DataRank · unranked

48 citations

Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Kenneth Byrd +12 more

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO Oncology Practice(2020)10.1200/jop.19.00133

N/A

0.477DataRank · unranked

23 citations

Megan Othus, Guillermo Garcia‐Manero, Min Fang, Jerald P. Radich, David A. Rizzieri +24 more

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148212

N/A

0.406DataRank · unranked

14 citations

Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby +15 more

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Blood(2021)10.1182/blood-2021-145529

N/A

0.396DataRank · unranked

13 citations

Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt +12 more

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Blood Advances(2025)10.1182/bloodadvances.2024013474

N/A

0.292DataRank · unranked

6 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +16 more

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Biomarker Research(2023)10.1186/s40364-023-00461-0

N/A

0.241DataRank · unranked

4 citations

Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +14 more

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Haematologica(2023)10.3324/haematol.2023.282733

N/A

0.165DataRank · unranked

2 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +10 more

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

medRxiv(2023)10.1101/2023.03.26.23287367

N/A

0DataRank · unranked

8 citations

Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith +8 more

Data from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia

(2023)10.1158/1078-0432.c.6518281

N/A

0DataRank · unranked

0 citations

Roxane Collins, Brian Parkin, Peter Ouillette, Erlene Kuizon, Lisa Kujawski +6 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more

Data from NF1 Inactivation in Adult Acute Myelogenous Leukemia

(2023)10.1158/1078-0432.c.6519537.v1

Top 100%

0DataRank

Top 100%0 citations

Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston +14 more

Data from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia

(2023)10.1158/1078-0432.c.6518281.v1

N/A

0DataRank · unranked

0 citations

Roxane Collins, Brian Parkin, Peter Ouillette, Erlene Kuizon, Lisa Kujawski +6 more

Supplementary Table S1 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia

(2023)10.1158/1078-0432.22441132

Top 100%

0DataRank

Top 100%0 citations

Roxane Collins, Brian Parkin, Peter Ouillette, Erlene Kuizon, Lisa Kujawski +6 more

Genomic Data Heterogeneity across Molecular Diagnostic Laboratories

Journal of Molecular Diagnostics(2023)10.1016/j.jmoldx.2023.05.002

N/A

0DataRank · unranked

0 citations

Harry P. Erba, Michael R. Savona, David L. Grinblatt, Maria Clark, Tyler C. Clive +7 more

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet Haematology(2020)10.1016/s2352-3026(20)30205-2

N/A

0DataRank · unranked

97 citations

Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal +47 more

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

Leukemia(2024)10.1038/s41375-024-02143-8

N/A

0DataRank · unranked

6 citations

Andrew H. Wei, Sumithra J. Mandrekar, Ing Soo Tiong, Chong Chyn Chua, Tse‐Chieh Teh +24 more

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report

eJHaem(2024)10.1002/jha2.1041

N/A

0DataRank · unranked

0 citations

Megan Othus, Chenwei Lin, Melinda A. Biernacki, Marie Bleakley, Thomas R. Chauncey +20 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065

N/A

0DataRank · unranked

2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more

Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024

Blood Cancer Journal(2025)10.1038/s41408-025-01294-w

N/A

0DataRank · unranked

2 citations

Alexis Berridge-Green, Megan Othus, Jerald P. Radich, Anjali S. Advani, Harry P. Erba +2 more

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203

Leukemia(2025)10.1038/s41375-024-02512-3

N/A

0DataRank · unranked

0 citations

Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Eliana Dietrich, Suravi Raychaudhuri +4 more

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Blood Neoplasia(2025)10.1016/j.bneo.2025.100129

N/A

0DataRank · unranked

0 citations

Megan Othus, Mary‐Elizabeth M. Percival, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba +2 more

Data from NF1 Inactivation in Adult Acute Myelogenous Leukemia

(2023)10.1158/1078-0432.c.6519537

Top 100%

0DataRank

Top 100%0 citations

Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston +14 more

Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1881512

N/A

0DataRank · unranked

2 citations

Megan Othus, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter +1 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20004

N/A

0DataRank · unranked

0 citations

Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander +15 more

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Research Square(2020)10.21203/rs.3.rs-24023/v1

N/A

0DataRank · unranked

3 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen +17 more

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2131416

N/A

0DataRank · unranked

0 citations

Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham +11 more

Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up

Value in Health(2020)10.1016/j.jval.2020.02.015

N/A

0DataRank · unranked

14 citations

Aasthaa Bansal, Harry P. Erba, Scott D. Ramsey, Megan Othus

Harry P. Erba

Indexed papers

Top data-sharing exemplar

Papers